<DOC>
	<DOC>NCT01956253</DOC>
	<brief_summary>This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.</brief_summary>
	<brief_title>Single Subject Neratinib in Bladder Cancer (NRR)</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>* none * none We have received FDA approval for a single subject Investigational New Drug (IND) Application to treat a specific patient with the HER2 kinase inhibitor neratinib. Therefore there is no inclusion / exclusion criteria.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Neratinib</keyword>
	<keyword>13-2526</keyword>
</DOC>